Immatics N.V. (IMTX)
IMTX Stock Price Chart
Explore Immatics N.V. interactive price chart. Choose custom timeframes to analyze IMTX price movements and trends.
IMTX Company Profile
Discover essential business fundamentals and corporate details for Immatics N.V. (IMTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Dec 2018
Employees
554.00
Website
https://www.immatics.comCEO
Harpreet Singh
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTX Financial Timeline
Browse a chronological timeline of Immatics N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Mar 2026
Upcoming earnings on 17 Nov 2025
EPS estimate is -$0.50.
Earnings released on 13 Aug 2025
EPS came in at -$0.66 falling short of the estimated -$0.38 by -73.68%, while revenue for the quarter reached $5.58M , missing expectations by -55.95%.
Earnings released on 13 May 2025
EPS came in at -$0.35 surpassing the estimated -$0.39 by +10.26%, while revenue for the quarter reached $20.37M , beating expectations by +50.79%.
Earnings released on 27 Mar 2025
EPS came in at $0.48 surpassing the estimated -$0.33 by +245.45%, while revenue for the quarter reached $58.25M , beating expectations by +145.60%.
Earnings released on 18 Nov 2024
EPS came in at -$0.12 surpassing the estimated -$0.27 by +55.56%, while revenue for the quarter reached $55.45M , beating expectations by +243.21%.
Earnings released on 13 Aug 2024
EPS came in at -$0.18 surpassing the estimated -$0.35 by +48.57%, while revenue for the quarter reached $20.17M , beating expectations by +35.34%.
Earnings released on 14 May 2024
EPS came in at -$0.04 surpassing the estimated -$0.74 by +94.59%, while revenue for the quarter reached $32.71M , beating expectations by +48.68%.
Earnings released on 21 Mar 2024
EPS came in at -$0.32 surpassing the estimated -$0.41 by +21.95%, while revenue for the quarter reached $17.51M , beating expectations by +6.96%.
Earnings released on 14 Nov 2023
EPS came in at -$0.35 surpassing the estimated -$0.42 by +16.67%, while revenue for the quarter reached $6.25M , missing expectations by -58.98%.
Earnings released on 17 Aug 2023
EPS came in at -$0.35 falling short of the estimated -$0.34 by -2.94%, while revenue for the quarter reached $24.39M , beating expectations by +9.50%.
Earnings released on 16 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.35 by +20.00%, while revenue for the quarter reached $10.65M , missing expectations by -17.76%.
Earnings released on 21 Mar 2023
EPS came in at -$0.23 falling short of the estimated $0.17 by -235.29%, while revenue for the quarter reached $40.55M , beating expectations by +78.73%.
Earnings released on 17 Nov 2022
EPS came in at -$0.32 falling short of the estimated -$0.31 by -3.23%, while revenue for the quarter reached $14.71M .
Earnings released on 9 Aug 2022
EPS came in at -$0.23 falling short of the estimated $0.13 by -276.92%, while revenue for the quarter reached $18.01M , missing expectations by -28.95%.
Earnings released on 2 Jun 2022
EPS came in at $1.35 falling short of the estimated $1.76 by -23.30%, while revenue for the quarter reached $113.83M , missing expectations by -28.13%.
Earnings released on 23 Mar 2022
EPS came in at -$0.30 falling short of the estimated $1.94 by -115.46%, while revenue for the quarter reached $17.83M , beating expectations by +65.99%.
Earnings released on 16 Nov 2021
EPS came in at -$0.51 falling short of the estimated -$0.31 by -64.52%, while revenue for the quarter reached $7.48M , missing expectations by -37.38%.
Earnings released on 10 Aug 2021
EPS came in at -$0.46 falling short of the estimated -$0.38 by -21.05%, while revenue for the quarter reached $6.16M , missing expectations by -38.50%.
Earnings released on 18 May 2021
EPS came in at -$0.41 falling short of the estimated -$0.34 by -20.59%, while revenue for the quarter reached $8.71M .
Earnings released on 30 Mar 2021
EPS came in at -$0.47 surpassing the estimated -$1.22 by +61.48%, while revenue for the quarter reached $11.58M .
Earnings released on 2 Dec 2020
EPS came in at -$0.46 falling short of the estimated -$0.31 by -48.39%, while revenue for the quarter reached $9.24M .
IMTX Stock Performance
Access detailed IMTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.